PHILADELPHIA, Feb. 25, 2008 (PRIME NEWSWIRE) -- Hemispherx Biopharma, Inc. (AMEX:HEB) today announced that it has accepted an invitation to present at the 2008 Emerging Growth Stock Conference, hosted by Jesup & Lamont, Inc., at the Walt Disney Contemporary Resort in Orlando FL, February 28, 2008 at 3:00 PM EST. A webcast of the presentation will be available on the Company's website at: www.hemispherx.net . A replay will be available for 30 days following the conference.
The Jesup & Lamont conference will feature 20 small and micro cap companies, each with fewer than five Wall Street analysts providing research coverage and, in the opinion of event organizers, having one or more growth catalysts. The Hemispherx presentation will focus on the Company's four technology platforms, including its progress in bringing a lead drug compound, Ampligen(r), an experimental therapeutic, to commercial fruition against Chronic Fatigue Syndrome ("CFS"). The Company will also discuss opportunities for Ampligen(r) to enhance both preventative and therapeutic vaccines against a variety of indications, including seasonal and pandemic influenza, HIV, cancer and other infectious diseases, and highlight other R&D efforts.
About Hemispherx Biopharma
Hemispherx Biopharma, Inc. is an advanced biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection(r) (FDA approved for a category of sexually transmitted diseases) and the experimental therapeutics Ampligen(r) and Oragens(r). Ampligen(r) and Oragens(r) represent experimental RNA nucleic acids being developed for globally important debilitating diseases and disorders of the immune system. Hemispherx's platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has in excess of 100 patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection(r)). The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States. For more information please visit http://www.hemispherx.net.
About Jesup & Lamont, Inc.
Jesup & Lamont, Inc. is a New York based full-service brokerage and investment banking firm providing institutional and retail sales and trading services, equity research and asset management for select clientele. The firm's specialty corporate finance activities include services and advice regarding mergers and acquisitions, capital raising, acquisition finance and restructurings with an emphasis on Healthcare, Alternative Energy and Aerospace & Defense contractors.
Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the Company (including Ampligen(r), Alferon LDO and Oragens) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Clinical trials for other potential indications of the approved biologic Alferon N Injection(r) do not imply that the product will ever be specifically approved commercially for these other treatment indications.